register

News - Pharmaceuticals

TGA approves first PARP inhibitor monotherapy in advanced ovarian cancer

Health Industry Hub | January 18, 2022 |

Pharma News: GSK Australia announced the Therapeutic Goods Administration (TGA) registration of its PARP inhibitor for the treatment of women with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer following completion of first-line platinum-based chemotherapy.

Zejula (niraparib) is currently the only PARP inhibitor approved by the TGA as a monotherapy for newly diagnosed women with advanced ovarian cancer who respond to platinum-based chemotherapy, regardless of whether or not they have a BRCA mutation.

Ovarian cancer affects around 1,500 Australian women every year.

“In order for women with advanced ovarian cancer to access a PARP inhibitor in Australia, their ovarian cancer must have responded to their initial chemotherapy and they need to have undergone testing to identify their BRCA mutation status” said Professor Clare Scott, Medical Oncologist, Peter MacCallum Cancer Centre.

“Only about 25% of those women have the BRCA mutation that will allow them to move onto an existing PARP inhibitor – meaning 75% of women after chemotherapy are left waiting with limited treatment options. With Zejula, all women whose cancers respond to chemotherapy now have the consideration of a PARP inhibitor. A larger proportion of these women will now be able to access this therapy that may delay their cancer from getting worse.”

In 2021, GSK was disappointed by the PBAC’s decision to not recommend Zejula. The PBAC noted the patient estimates presented in the submission to be “overestimated and the cost to be underestimated”. The PBAC considered that a resubmission would need to address the “uncertainty in the clinical claims by demonstrating an overall survival benefit for niraparib compared with standard medical management. In addition, substantial revisions to the economic models and financial estimates would be required.”

“This milestone is a significant part of GSK Oncology’s commitment to providing more options to patients, and more specifically our commitment to women’s cancers,” said Patrick Desbiens, General Manager of GSK Australia & New Zealand.”


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.